2017 Annual Report 1 I Sirtex 2017 Highlights
2017 ANNUAL REPORT 1 I SIRTEX 2017 HIGHLIGHTS DOSES SOLD 2017 12,578 14,000 12,000 10,000 8,000 6,000 4,000 2,000 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 CONTENTS ABOUT SIRTEX 03 2017 FINANCIAL SUMMARY Sirtex Medical Limited is an Australian- 05 CHAIRMAN’S REPORT based global healthcare business working to 09 CHIEF EXECUTIVE OFFICER’S REPORT improve outcomes for people with cancer. 18 ENVIRONMENTAL, SOCIAL AND Our lead product is a targeted radiation GOVERNANCE therapy known as SIR-Spheres® Y-90 resin 22 BOARD OF DIRECTORS microspheres. It is available in more than 23 KEY MANAGEMENT PERSONNEL 40 countries, within over 1,090 certified hospitals to treat patients with 24 FINANCIAL REPORT inoperable liver cancer. Our business revolves around helping medical professionals understand and use our product to improve clinical outcomes and the quality of life for people with liver cancer. While at the same time, we work closely with government and private payers to ensure our patients receive the appropriate reimbursement for our product. We are challenging established practices and developing innovative new therapies that promise to improve the health and lives of many people suffering from cancer or other diseases. Our ongoing success is based on a commitment to serving our customers, professionalism, continuous improvement and innovation. ANNUAL REPORT 2017 I 2 DOSE SALES 12,578 +5.4% REVENUE $234.3m +0.8% NET LOSS AFTER TAX $26.3m -149.0% THE AMERICAS EUROPE, MIDDLE ASIA PACIFIC EAST, AFRICA Boston, United States Frankfurt,
[Show full text]